iPS Cells & Regenerative Medicine Weekly Report July 12, 2026

iPS Cells & Regenerative Medicine Weekly Report August 9, 2026

Lineage Cell Therapeutics Continues Support for Roche/Genentech’s OpRegen Cell Therapy, AlloSCOPE™ Platform Enables Scalable Manufacturing

CAR-T Cell Therapy Established for Specific B-Cell Lymphomas/Leukemias, but Product Differentiation and Individualized Adaptation Crucial

Cell Therapy Clinical Success Hinges on Manufacturability: Limitations of Autologous Therapies Drive Interest in Allogeneic ‘Off-the-Shelf’ Platforms

EVERSANA Selected as Commercialization Partner for Innovacell Inc.’s Novel Cell Therapy ICEF15 for Urgent Fecal Incontinence in the United States

China’s First Approved MSC Therapy, Ruibosheng, Launched at Fraction of Global Price, Receives Conditional Approval for Severe GVHD

Fate Therapeutics Executives Sell Shares Post-FDA IND Approval for Next-Gen Autoimmune CAR-T Candidate FT839, Market Anticipates Basket Trial Success

Real-World Data Evaluates Incidence and Management of Cytokine Release Syndrome and Neurotoxicity Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel CAR-T Cell Therapy Across 87 U.S. Centers